Amir Kaykha, MD
Interventional Cardiology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 28
- 7 carriers
- Office
- 1
Offices
1 location
Hospitals listed: El Camino Health · Good Samaritan Hospital · Santa Clara Valley Medical Center · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
28 plans · 7 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kaykha’s office at (408) 292-7777 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
28 of 28 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$1,168,178
Medicare paid this office $1,168,178 for 572 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 239 | $408,846 | $1,696 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 239 | $212,386 | $442 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 115 | $126,225 | $978 |
| Return visit (30+ min) | 452 | $119,553 | $124 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 299 | $65,983 | $207 |
See all 38 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 239 | $408,846 | $1,696 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 239 | $212,386 | $442 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 115 | $126,225 | $978 |
| Return visit (30+ min) | 452 | $119,553 | $124 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 299 | $65,983 | $207 |
| Ultrasound of both sides of head and neck blood flow | 100 | $21,422 | $212 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 19 | $21,083 | $116 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 241 | $19,185 | $79 |
| Critical care, first 30-74 minutes | 31 | $17,035 | $200 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 475 | $15,654 | $14 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $15,249 | $115 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 22 | $11,191 | $487 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 58 | $10,382 | $165 |
| Injection of drug or substance into vein | 240 | $10,204 | $42 |
| Long return visit (40+ min) | 46 | $9,325 | $179 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 38 | $7,924 | $198 |
| New patient visit (45+ min) | 46 | $7,351 | $160 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 101 | $7,068 | $66 |
| Balloon dilation of single coronary artery or branch | 23 | $5,850 | $244 |
| Injection, regadenoson, 0.1 mg | 236 | $5,521 | None |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 54 | $4,404 | $25 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 42 | $3,820 | $27 |
| Ultrasound of leg arteries at rest and after exercise | 15 | $3,743 | $187 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 115 | $3,014 | $23 |
| Programming of dual lead pacemaker system | 23 | $2,549 | $82 |
| Short return visit (20+ min) | 24 | $2,377 | $91 |
| Evaluation of implantable heart and blood vessel monitoring system | 30 | $2,330 | $49 |
| Ultrasound study of arm and leg arteries | 15 | $1,925 | $96 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 20 | $1,783 | $85 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 14 | $1,412 | $34 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $1,122 | $102 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 11 | $714 | $65 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 51 | $646 | $11 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 17 | $418 | $25 |
| Ultrasound of heart blood flow, valves and chambers | 11 | $189 | $17 |
| Heart rhythm recording of continous external ekg over 8-15 days | 11 | $154 | $14 |
| Infusion, normal saline solution, 250 cc | 241 | $125 | None |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 11 | $33 | $3 |
Procedures Medicare counted
| Coronary angioplasty and stenting | 50 | More than 82% of doctors who do this |
Who their Medicare patients are
572 Original Medicare patients in 2024. Average age 78 · Women 43% · Also on Medicaid 20% · Health risk score 1.60. At or below the middle of the specialty; the typical interventional cardiology clinician is at 1.7.
Conditions among them: High blood pressure 75% · Coronary heart disease 75% · Diabetes 41% · Atrial fibrillation 39% · Heart failure 32% · Chronic kidney disease 30% · COPD 17% · Stroke 17% · Cancer 15% · Depression 15% · Dementia 13%.
The office billed $2,480,896, Medicare allowed $1,467,324 and paid $1,168,178; for 6,705 services of 65 kinds; $5,678 of it was for drugs given in the office and $1,162,500 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 572 | 6,705 | 78 | 1.60 | $2,480,896 | $1,168,178 |
| 2023 | 581 | 12,395 | 79 | 1.51 | $2,091,095 | $965,324 |
| 2022 | 577 | 16,780 | 78 | 1.48 | $2,377,032 | $1,137,093 |
| 2021 | 631 | 18,591 | 78 | 1.43 | $2,623,777 | $1,261,022 |
| 2020 | 600 | 17,150 | 78 | 1.59 | $2,429,873 | $1,151,934 |
| 2019 | 525 | 17,369 | 77 | 1.69 | $1,923,948 | $839,511 |
| 2018 | 503 | 11,932 | 77 | 1.89 | $1,376,531 | $592,075 |
| 2017 | 380 | 2,398 | 78 | 2.15 | $658,493 | $313,820 |
| 2016 | 337 | 2,171 | 76 | 2.18 | $953,262 | $290,483 |
| 2015 | 275 | 1,641 | 76 | 1.91 | $302,564 | $166,127 |
| 2014 | 268 | 1,292 | 76 | 2.10 | $190,568 | $95,294 |
| 2013 | 324 | 1,864 | 77 | 1.81 | $337,858 | $134,475 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 34 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 202 | $324,534 | $1,607 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 203 | $169,049 | $417 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 116 | $118,291 | $954 |
| Return visit (30+ min) | 450 | $101,989 | $114 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 270 | $56,550 | $197 |
| Critical care, first 30-74 minutes | 29 | $18,777 | $192 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 204 | $14,888 | $73 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 492 | $13,958 | $13 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $13,713 | $110 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 59 | $9,776 | $155 |
| Ultrasound of both sides of head and neck blood flow | 46 | $8,851 | $192 |
| Injection of drug or substance into vein | 203 | $8,211 | $40 |
| New patient visit (45+ min) | 50 | $7,037 | $141 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 28 | $6,184 | $213 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 90 | $5,954 | $63 |
| Ultrasound of leg arteries at rest and after exercise | 31 | $5,406 | $169 |
| Injection, regadenoson, 0.1 mg | 45 | $4,910 | None |
| Short return visit (20+ min) | 60 | $4,837 | $77 |
| Long return visit (40+ min) | 25 | $4,083 | $151 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 49 | $3,787 | $24 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 11 | $3,773 | $36 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 40 | $3,246 | $26 |
| Programming of dual lead pacemaker system | 24 | $2,977 | $78 |
| Ultrasound study of arm and leg arteries | 31 | $2,896 | $91 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 158 | $2,870 | None |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 116 | $2,738 | $22 |
| Balloon dilation of single coronary artery or branch | 11 | $2,688 | $224 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 11 | $2,474 | $24 |
| Evaluation of implantable heart and blood vessel monitoring system | 33 | $2,394 | $46 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 12 | $1,089 | $33 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 12 | $1,057 | $81 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 37 | $429 | $11 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 11 | $142 | $13 |
| Infusion, normal saline solution, 250 cc | 203 | $103 | None |
2022: 29 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 249 | $401,062 | $1,604 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 249 | $208,571 | $417 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 151 | $164,889 | $1,005 |
| Return visit (30+ min) | 462 | $114,842 | $113 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 340 | $74,196 | $202 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 249 | $18,222 | $73 |
| Ultrasound of both sides of head and neck blood flow | 82 | $16,748 | $204 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 497 | $14,832 | $13 |
| Critical care, first 30-74 minutes | 23 | $12,954 | $196 |
| Injection of drug or substance into vein | 249 | $10,637 | $43 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $9,184 | $177 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $9,166 | $94 |
| New patient visit (45+ min) | 57 | $7,958 | $140 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 30 | $6,822 | $220 |
| Ultrasound of leg arteries at rest and after exercise | 30 | $5,583 | $174 |
| Short return visit (20+ min) | 64 | $5,434 | $82 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 248 | $4,204 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 59 | $4,146 | $65 |
| Programming of dual lead pacemaker system | 34 | $3,734 | $79 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 151 | $3,685 | $22 |
| Balloon dilation of single coronary artery or branch | 11 | $3,642 | $243 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 45 | $3,032 | $26 |
| Evaluation of implantable heart and blood vessel monitoring system | 42 | $2,985 | $48 |
| Ultrasound study of arm and leg arteries | 30 | $2,894 | $90 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 38 | $2,840 | $28 |
| Long return visit (40+ min) | 16 | $2,619 | $154 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 12 | $1,242 | $83 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 47 | $579 | $11 |
| Infusion, normal saline solution, 250 cc | 249 | $131 | None |
2021: 31 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 279 | $462,926 | $1,659 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 280 | $236,373 | $423 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 180 | $154,291 | $799 |
| Return visit (30+ min) | 470 | $117,212 | $119 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 325 | $70,693 | $210 |
| Ultrasound of both sides of head and neck blood flow | 115 | $24,426 | $212 |
| Critical care, first 30-74 minutes | 27 | $22,822 | $200 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 258 | $18,879 | $73 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 512 | $16,202 | $14 |
| New patient visit (45+ min) | 108 | $14,078 | $130 |
| Short return visit (20+ min) | 132 | $12,619 | $81 |
| Injection of drug or substance into vein | 278 | $12,513 | $45 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $12,081 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 61 | $12,067 | $186 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 36 | $8,098 | $202 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 15 | $7,511 | $442 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 278 | $5,857 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 79 | $5,636 | $66 |
| Balloon dilation of single coronary artery or branch | 17 | $4,890 | $245 |
| Programming of dual lead pacemaker system | 40 | $4,785 | $76 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 181 | $4,457 | $23 |
| Ultrasound of leg arteries at rest and after exercise | 24 | $4,206 | $175 |
| Evaluation of implantable heart and blood vessel monitoring system | 53 | $3,790 | $44 |
| Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | 12 | $3,271 | $273 |
| Long return visit (40+ min) | 11 | $2,303 | $177 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 15 | $1,438 | $85 |
| Ultrasound study of arm and leg arteries | 12 | $1,135 | $95 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 22 | $976 | $28 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 14 | $656 | $29 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 48 | $611 | $12 |
| Infusion, normal saline solution, 250 cc | 280 | $154 | None |
2020: 29 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 262 | $441,016 | $1,677 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 262 | $221,577 | $421 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 154 | $130,277 | $790 |
| Return visit (30+ min) | 412 | $85,194 | $100 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 347 | $77,203 | $216 |
| New patient visit (45+ min) | 176 | $26,218 | $149 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 263 | $19,222 | $73 |
| Ultrasound of both sides of head and neck blood flow | 86 | $18,457 | $215 |
| Critical care, first 30-74 minutes | 26 | $13,233 | $204 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 436 | $11,266 | $16 |
| Injection of drug or substance into vein | 261 | $11,090 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 49 | $10,563 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $9,762 | $188 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 14 | $8,219 | $433 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 33 | $7,626 | $218 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 87 | $6,470 | $69 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 261 | $5,856 | None |
| Balloon dilation of single coronary artery or branch | 15 | $5,008 | $250 |
| Short return visit (20+ min) | 59 | $4,660 | $73 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 154 | $4,030 | $24 |
| Evaluation of implantable heart and blood vessel monitoring system | 51 | $3,671 | $42 |
| New patient visit (60+ min) | 18 | $3,604 | $200 |
| Long return visit (40+ min) | 21 | $3,563 | $143 |
| Programming of dual lead pacemaker system | 34 | $3,493 | $70 |
| Ultrasound of leg arteries at rest and after exercise | 13 | $2,324 | $179 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 14 | $1,293 | $86 |
| Telephone medical discussion with physician, 21-30 minutes | 13 | $1,143 | $88 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 40 | $514 | $11 |
| Infusion, normal saline solution, 250 cc | 263 | $134 | None |
2019: 32 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 200 | $307,534 | $1,538 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 200 | $163,308 | $408 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 93 | $75,792 | $758 |
| Return visit (30+ min) | 349 | $69,502 | $96 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 232 | $50,437 | $206 |
| Critical care, first 30-74 minutes | 35 | $20,882 | $195 |
| Ultrasound of both sides of head and neck blood flow | 71 | $14,531 | $205 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 202 | $14,116 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 69 | $13,706 | $92 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 394 | $13,422 | $16 |
| New patient visit (45+ min) | 90 | $12,576 | $140 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 58 | $10,888 | $178 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 40 | $8,626 | $216 |
| Injection of drug or substance into vein | 199 | $7,992 | $40 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 201 | $7,403 | None |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 14 | $6,842 | $489 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 91 | $6,273 | $66 |
| Long return visit (40+ min) | 34 | $5,149 | $129 |
| Programming of dual lead pacemaker system | 32 | $3,163 | $60 |
| Ultrasound of leg arteries at rest and after exercise | 14 | $2,421 | $173 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 96 | $2,327 | $23 |
| Evaluation of implantable heart and blood vessel monitoring system | 32 | $1,946 | $36 |
| External ekg recording for more than 48 hours up to 21 days with analysis, report, review and interpretation | 19 | $1,819 | $91 |
| Ultrasound scan of abdominal aorta | 11 | $1,610 | $146 |
| Ultrasound of heart with probe in esophagus, with report | 13 | $1,286 | $99 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 14 | $1,164 | $83 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 53 | $732 | $11 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 14 | $627 | $27 |
| Ultrasound of heart blood flow, valves and chambers | 13 | $217 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 11 | $149 | $14 |
| Infusion, normal saline solution, 250 cc | 202 | $98 | None |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 13 | $38 | $3 |
2018: 28 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 148 | $204,031 | $1,369 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 135 | $100,480 | $388 |
| Return visit (30+ min) | 262 | $44,860 | $94 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 182 | $38,167 | $202 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 40 | $30,555 | $764 |
| Critical care, first 30-74 minutes | 49 | $23,953 | $190 |
| New patient visit (45+ min) | 170 | $23,932 | $141 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 89 | $16,164 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 74 | $13,675 | $175 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 366 | $10,497 | $15 |
| Ultrasound of both sides of head and neck blood flow | 53 | $10,313 | $195 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 148 | $10,076 | $68 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 42 | $9,055 | $216 |
| Injection of drug or substance into vein | 148 | $6,958 | $47 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 12 | $5,399 | $450 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 146 | $5,279 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 80 | $5,237 | $65 |
| New patient visit (60+ min) | 23 | $4,270 | $186 |
| Long return visit (40+ min) | 23 | $3,441 | $132 |
| Programming of dual lead pacemaker system | 33 | $2,633 | $51 |
| Ultrasound of heart with probe in esophagus, with report | 12 | $1,150 | $96 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 13 | $1,041 | $80 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 43 | $980 | $23 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 12 | $967 | $81 |
| Short return visit (20+ min) | 13 | $942 | $63 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 54 | $877 | $11 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 16 | $209 | $13 |
| Infusion, normal saline solution, 250 cc | 151 | $74 | None |
2017: 24 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 76 | $110,077 | $1,448 |
| Critical care, first 30-74 minutes | 40 | $30,900 | $183 |
| Return visit (30+ min) | 179 | $29,115 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 111 | $23,688 | $87 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 84 | $18,834 | $214 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 78 | $16,756 | $215 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 85 | $16,249 | $168 |
| New patient visit (45+ min) | 76 | $10,123 | $133 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 133 | $7,642 | $54 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 217 | $6,312 | $14 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 28 | $5,989 | $214 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 75 | $5,272 | $70 |
| Injection of drug or substance into vein | 80 | $4,348 | $54 |
| Ultrasound of leg arteries or artery grafts | 16 | $4,032 | $252 |
| Ultrasound of both sides of head and neck blood flow | 20 | $4,017 | $191 |
| Short return visit (20+ min) | 34 | $2,019 | $56 |
| Critical care, each additional 30 minutes | 12 | $1,650 | $92 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $1,011 | $92 |
| Ultrasound study of arm and leg arteries | 12 | $939 | $78 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 25 | $326 | $13 |
| Ultrasound of heart blood flow, valves and chambers | 11 | $171 | $16 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 76 | $35 | None |
| Infusion, normal saline solution, 250 cc | 80 | $32 | None |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 11 | $30 | $3 |
2016: 20 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 78 | $112,862 | $1,429 |
| Return visit (30+ min) | 143 | $23,281 | $91 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 77 | $21,827 | $230 |
| Critical care, first 30-74 minutes | 34 | $20,860 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 74 | $20,105 | $92 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 64 | $11,383 | $170 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $10,569 | $179 |
| New patient visit (45+ min) | 67 | $9,838 | $147 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 121 | $7,168 | $56 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 191 | $6,391 | $15 |
| Short return visit (20+ min) | 73 | $6,250 | $60 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 77 | $5,759 | $74 |
| Injection of drug or substance into vein | 73 | $4,244 | $58 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 15 | $3,485 | $218 |
| Ultrasound of both sides of head and neck blood flow | 17 | $3,190 | $188 |
| Ultrasound of leg arteries or artery grafts | 13 | $2,389 | $184 |
| Emergency department visit with moderate level of medical decision making | 15 | $1,440 | $96 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 33 | $418 | $13 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 77 | $45 | None |
| Infusion, normal saline solution, 250 cc | 77 | $30 | None |
2015: 21 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 21 | $30,227 | $1,439 |
| Critical care, first 30-74 minutes | 35 | $21,111 | $195 |
| Return visit (30+ min) | 99 | $17,404 | $94 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 53 | $12,321 | $228 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $12,200 | $92 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 21 | $9,427 | $230 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $8,499 | $177 |
| Short return visit (20+ min) | 92 | $8,024 | $61 |
| New patient visit (45+ min) | 51 | $7,184 | $141 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 154 | $5,573 | $14 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 88 | $5,033 | $56 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 17 | $3,411 | $201 |
| Ultrasound of both sides of head and neck blood flow | 13 | $2,252 | $173 |
| Insertion of tube in left heart chambers for diagnosis with review by radiologist | 13 | $1,714 | $132 |
| Ultrasound of heart for congenital defect | 26 | $1,550 | $55 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 21 | $1,548 | $74 |
| Ultrasound of heart with probe in esophagus, with report | 12 | $1,329 | $95 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 43 | $562 | $13 |
| Iliac and/or femoral artery angiography, non-selective, bilateral or ipsilateral to catheter insertion, performed at the same time as cardiac catheterization and/or coronary angiography, includes positioning or placement of the catheter in the distal aorta | 17 | $211 | $11 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 21 | $16 | None |
| Infusion, normal saline solution, 250 cc | 21 | $10 | None |
2014: 17 services
| Return visit (30+ min) | 123 | $22,117 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $9,334 | $92 |
| New patient visit (45+ min) | 55 | $8,215 | $149 |
| Critical care, first 30-74 minutes | 13 | $7,037 | $195 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 53 | $6,517 | $123 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $5,512 | $178 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 164 | $5,227 | $16 |
| Short return visit (20+ min) | 53 | $4,667 | $67 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 75 | $4,416 | $57 |
| Critical care, each additional 30 minutes | 11 | $2,543 | $98 |
| Ultrasound of both sides of head and neck blood flow | 24 | $1,734 | $72 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 15 | $1,106 | $74 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 14 | $924 | $66 |
| Electrocardiogram (ecg) 2-day continuous | 11 | $292 | $27 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 11 | $267 | $24 |
| Injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270) | 14 | $34 | None |
| Infusion, normal saline solution, 250 cc | 14 | $7 | None |
2013: 24 services
| Return visit (30+ min) | 133 | $25,617 | $83 |
| Critical care, first 30-74 minutes | 20 | $12,567 | $190 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $12,508 | $89 |
| New patient visit (45+ min) | 84 | $10,217 | $122 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 55 | $9,753 | $174 |
| Removal of plaque, insertion of stent and balloon dilation of single coronary artery or branch | 15 | $8,379 | $559 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 169 | $7,798 | $17 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 107 | $6,113 | $54 |
| Insertion of tube in left heart chambers for diagnosis with review by radiologist | 36 | $6,106 | $170 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 71 | $6,044 | $81 |
| Critical care, each additional 30 minutes | 17 | $4,395 | $96 |
| Short return visit (20+ min) | 51 | $3,306 | $52 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 46 | $3,207 | $68 |
| Initial hospital care with same-day admission and discharge with high level of medical decision making, per day at least 85 minutes | 11 | $2,058 | $187 |
| Ultrasound of both sides of head and neck blood flow | 47 | $1,546 | $32 |
| Ultrasound of heart with probe in esophagus, with report | 16 | $1,445 | $90 |
| Ultrasound study of arm and leg arteries | 18 | $1,298 | $72 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 41 | $807 | $19 |
| Ultrasound of heart for congenital defect | 14 | $776 | $55 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 41 | $535 | $13 |
| Iliac and/or femoral artery angiography, non-selective, bilateral or ipsilateral to catheter insertion, performed at the same time as cardiac catheterization and/or coronary angiography, includes positioning or placement of the catheter in the distal aorta | 37 | $392 | $11 |
| Ultrasound of heart blood flow, valves and chambers | 15 | $241 | $16 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 15 | $93 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 14 | $45 | $3 |
Medicaid work
$684 in 2023
Medicaid paid $684 for 51 billed services this clinician did in 2023, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 14 | $615 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 37 | $69 |
| 2023 | 51 | 2 | 14 | $684 |
| 2021 | 46 | 2 | 16 | $62 |
| 2020 | 13 | 1 | 13 | $79 |
| 2019 | 12 | 1 | 12 | $59 |
See the largest Medicaid services in earlier years
2021
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 33 | $62 |
| Return visit (30+ min) | 13 | $0 |
2020
| Return visit (30+ min) | 13 | $79 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 12 | $59 |
Drugs they prescribed that Part D paid
$1,370,493
Pharmacies billed $1,370,493 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 4,991) in 2024. At or below the middle of the specialty; the typical interventional cardiology clinician is at 0%.
3,956 generic and 1,035 brand-name prescriptions · $1,370,493 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 329 | $453,697 | $1,379 |
| Xarelto | 144 | $194,691 | $1,352 |
| Entresto | 129 | $156,153 | $1,210 |
| Repatha Sureclick | 87 | $84,039 | $966 |
| Farxiga | 64 | $83,957 | $1,312 |
See all 47 drugs
| Eliquis | 329 | $453,697 | $1,379 |
| Xarelto | 144 | $194,691 | $1,352 |
| Entresto | 129 | $156,153 | $1,210 |
| Repatha Sureclick | 87 | $84,039 | $966 |
| Farxiga | 64 | $83,957 | $1,312 |
| Brilinta | 79 | $74,637 | $945 |
| Vascepa | 69 | $45,081 | $653 |
| Ranolazine Er | 169 | $33,114 | $196 |
| Verquvo | 21 | $31,332 | $1,492 |
| Jardiance | 15 | $22,663 | $1,511 |
| Praluent | 20 | $20,831 | $1,042 |
| Icosapent Ethyl | 59 | $19,021 | $322 |
| Veltassa | 14 | $10,048 | $718 |
| Metoprolol | 567 | $8,479 | $15 |
| Rosuvastatin | 200 | $4,687 | $23 |
| Amiodarone | 67 | $4,465 | $67 |
| Atorvastatin | 363 | $4,194 | $12 |
| Losartan | 333 | $3,338 | $10 |
| Isosorbide Mononitrate Er | 151 | $2,639 | $17 |
| Valsartan | 58 | $2,190 | $38 |
| Hydralazine | 126 | $1,957 | $16 |
| Sotalol | 110 | $1,943 | $18 |
| Nebivolol | 25 | $1,942 | $78 |
| Ezetimibe | 60 | $1,839 | $31 |
| Prasugrel | 23 | $1,681 | $73 |
| Amlodipine Besylate | 231 | $1,566 | $7 |
| Bisoprolol | 83 | $1,454 | $18 |
| Carvedilol | 94 | $1,351 | $14 |
| Pravastatin | 91 | $1,244 | $14 |
| Clopidogrel | 74 | $1,171 | $16 |
| Metoprolol | 120 | $988 | $8 |
| Spironolactone | 153 | $978 | $6 |
| Lisinopril | 128 | $930 | $7 |
| Hydrochlorothiazide | 115 | $659 | $6 |
| Digoxin | 30 | $627 | $21 |
| Valsartan-Hydrochlorothiazide | 14 | $527 | $38 |
| Flecainide Acetate | 13 | $484 | $37 |
| Furosemide | 80 | $455 | $6 |
| Nitroglycerin | 36 | $417 | $12 |
| Simvastatin | 21 | $364 | $17 |
| Levothyroxine | 26 | $330 | $13 |
| Metformin | 19 | $239 | $13 |
| Losartan-Hydrochlorothiazide | 28 | $222 | $8 |
| Benazepril | 16 | $182 | $11 |
| Atenolol | 17 | $106 | $6 |
| Clonidine | 17 | $73 | $4 |
| Gabapentin | 11 | $65 | $6 |
Year by year
| 2024 | 4,991 | 501 | 0% (0) | 21% | $1,370,493 |
| 2023 | 5,250 | 513 | 0% (0) | None | $1,499,582 |
| 2022 | 5,453 | 524 | 0% (0) | 19% | $1,423,066 |
| 2021 | 5,308 | 535 | 0% (0) | 19% | $1,196,782 |
| 2020 | 3,752 | 446 | 0% (0) | 20% | $720,712 |
| 2019 | 3,194 | 328 | 0% (0) | 20% | $498,876 |
| 2018 | 2,106 | 246 | None | 19% | $235,679 |
| 2017 | 1,547 | 147 | 0% (0) | 25% | $170,388 |
| 2016 | 1,153 | 113 | None | 27% | $108,582 |
| 2015 | 1,028 | 109 | 0% (0) | 24% | $84,861 |
| 2014 | 1,493 | 126 | None | 31% | $122,188 |
| 2013 | 1,177 | 121 | None | 33% | $80,278 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 51 drugs
| Eliquis | 346 | $483,758 | $1,398 |
| Xarelto | 182 | $237,497 | $1,305 |
| Entresto | 122 | $173,499 | $1,422 |
| Farxiga | 80 | $113,311 | $1,416 |
| Repatha Sureclick | 88 | $91,383 | $1,038 |
| Vascepa | 57 | $52,727 | $925 |
| Brilinta | 57 | $51,825 | $909 |
| Ranolazine Er | 184 | $47,694 | $259 |
| Verquvo | 28 | $36,607 | $1,307 |
| Praluent | 34 | $33,358 | $981 |
| Icosapent Ethyl | 37 | $23,988 | $648 |
| Metoprolol | 577 | $11,938 | $21 |
| Veltassa | 16 | $8,464 | $529 |
| Livalo | 12 | $8,002 | $667 |
| Rosuvastatin | 196 | $6,917 | $35 |
| Atorvastatin | 374 | $5,438 | $15 |
| Isosorbide Mononitrate Er | 182 | $5,374 | $30 |
| Losartan | 338 | $5,165 | $15 |
| Nebivolol | 44 | $5,087 | $116 |
| Amiodarone | 64 | $4,575 | $71 |
| Sotalol | 110 | $4,258 | $39 |
| Prasugrel | 24 | $3,322 | $138 |
| Ezetimibe | 52 | $2,896 | $56 |
| Hydralazine | 127 | $2,830 | $22 |
| Amlodipine Besylate | 255 | $2,750 | $11 |
| Valsartan | 41 | $2,318 | $57 |
| Bisoprolol | 64 | $2,138 | $33 |
| Pravastatin | 115 | $2,053 | $18 |
| Lisinopril | 143 | $2,002 | $14 |
| Flecainide Acetate | 23 | $1,896 | $82 |
| Carvedilol | 101 | $1,652 | $16 |
| Metoprolol | 130 | $1,442 | $11 |
| Digoxin | 38 | $1,389 | $37 |
| Spironolactone | 162 | $1,369 | $8 |
| Bumetanide | 11 | $1,065 | $97 |
| Hydrochlorothiazide | 133 | $1,041 | $8 |
| Clopidogrel | 46 | $936 | $20 |
| Furosemide | 104 | $844 | $8 |
| Diltiazem 24hr Er (Cd) | 13 | $703 | $54 |
| Nitroglycerin | 37 | $604 | $16 |
| Valsartan-Hydrochlorothiazide | 21 | $603 | $29 |
| Losartan-Hydrochlorothiazide | 22 | $435 | $20 |
| Levothyroxine | 25 | $401 | $16 |
| Finasteride | 12 | $340 | $28 |
| Simvastatin | 29 | $261 | $9 |
| Potassium Chloride | 13 | $254 | $20 |
| Warfarin | 24 | $227 | $9 |
| Clonidine | 23 | $205 | $9 |
| Atenolol | 21 | $172 | $8 |
| Pantoprazole | 11 | $134 | $12 |
| Benazepril | 11 | $120 | $11 |
2022: 52 drugs
| Eliquis | 301 | $411,223 | $1,366 |
| Xarelto | 186 | $233,838 | $1,257 |
| Entresto | 140 | $192,033 | $1,372 |
| Farxiga | 88 | $116,536 | $1,324 |
| Brilinta | 48 | $56,115 | $1,169 |
| Vascepa | 57 | $54,803 | $961 |
| Ranolazine Er | 186 | $53,621 | $288 |
| Repatha Sureclick | 37 | $47,702 | $1,289 |
| Verquvo | 31 | $31,471 | $1,015 |
| Icosapent Ethyl | 41 | $28,735 | $701 |
| Praluent | 18 | $15,044 | $836 |
| Livalo | 14 | $11,947 | $853 |
| Metoprolol | 556 | $10,472 | $19 |
| Prasugrel | 46 | $9,615 | $209 |
| Rosuvastatin | 148 | $5,874 | $40 |
| Atorvastatin | 402 | $5,124 | $13 |
| Nebivolol | 38 | $4,949 | $130 |
| Ezetimibe | 57 | $4,545 | $80 |
| Isosorbide Mononitrate Er | 172 | $4,267 | $25 |
| Sotalol | 104 | $4,137 | $40 |
| Losartan | 372 | $4,079 | $11 |
| Valsartan | 41 | $3,712 | $91 |
| Flecainide Acetate | 34 | $3,351 | $99 |
| Hydralazine | 129 | $2,771 | $21 |
| Bisoprolol | 53 | $2,649 | $50 |
| Amiodarone | 84 | $2,568 | $31 |
| Pravastatin | 159 | $2,299 | $14 |
| Amlodipine Besylate | 244 | $2,228 | $9 |
| Valsartan-Hydrochlorothiazide | 26 | $2,191 | $84 |
| Digoxin | 50 | $1,971 | $39 |
| Carvedilol | 117 | $1,736 | $15 |
| Lisinopril | 177 | $1,684 | $10 |
| Metoprolol | 146 | $1,571 | $11 |
| Spironolactone | 176 | $1,446 | $8 |
| Hydrochlorothiazide | 148 | $1,087 | $7 |
| Nitroglycerin | 50 | $1,074 | $21 |
| Diltiazem 24hr Er (Cd) | 25 | $1,006 | $40 |
| Losartan-Hydrochlorothiazide | 28 | $960 | $34 |
| Diltiazem 24hr Er (Xr) | 14 | $957 | $68 |
| Clopidogrel | 49 | $909 | $19 |
| Furosemide | 127 | $831 | $7 |
| Levothyroxine | 27 | $700 | $26 |
| Potassium Chloride | 20 | $472 | $24 |
| Simvastatin | 45 | $434 | $10 |
| Pantoprazole | 14 | $417 | $30 |
| Warfarin | 18 | $394 | $22 |
| Finasteride | 15 | $392 | $26 |
| Verapamil Er | 13 | $293 | $23 |
| Clonidine | 26 | $144 | $6 |
| Atenolol | 19 | $134 | $7 |
| Ramipril | 14 | $83 | $6 |
| Metformin | 13 | $60 | $5 |
2021: 52 drugs
| Eliquis | 330 | $409,628 | $1,241 |
| Xarelto | 178 | $208,320 | $1,170 |
| Entresto | 90 | $113,107 | $1,257 |
| Vascepa | 121 | $97,631 | $807 |
| Brilinta | 68 | $63,794 | $938 |
| Ranolazine Er | 167 | $39,658 | $237 |
| Farxiga | 30 | $35,154 | $1,172 |
| Repatha Sureclick | 22 | $26,361 | $1,198 |
| Icosapent Ethyl | 40 | $16,570 | $414 |
| Livalo | 21 | $14,452 | $688 |
| Metoprolol | 541 | $11,683 | $22 |
| Bystolic | 32 | $10,834 | $339 |
| Atorvastatin | 413 | $7,412 | $18 |
| Sotalol | 120 | $5,730 | $48 |
| Prasugrel | 27 | $5,562 | $206 |
| Losartan | 365 | $5,479 | $15 |
| Rosuvastatin | 126 | $5,129 | $41 |
| Isosorbide Mononitrate Er | 128 | $4,161 | $33 |
| Flecainide Acetate | 36 | $4,145 | $115 |
| Amiodarone | 66 | $4,051 | $61 |
| Bisoprolol | 45 | $3,257 | $72 |
| Pravastatin | 169 | $2,793 | $17 |
| Amlodipine Besylate | 242 | $2,788 | $12 |
| Losartan-Hydrochlorothiazide | 41 | $2,748 | $67 |
| Valsartan | 26 | $2,674 | $103 |
| Hydralazine | 106 | $2,455 | $23 |
| Ezetimibe | 47 | $2,407 | $51 |
| Lisinopril | 207 | $2,352 | $11 |
| Digoxin | 44 | $2,173 | $49 |
| Isosorbide Dinitrate | 13 | $2,037 | $157 |
| Carvedilol | 124 | $2,026 | $16 |
| Metoprolol | 177 | $1,827 | $10 |
| Valsartan-Hydrochlorothiazide | 21 | $1,703 | $81 |
| Clopidogrel | 78 | $1,429 | $18 |
| Nitroglycerin | 67 | $1,315 | $20 |
| Hydrochlorothiazide | 137 | $1,264 | $9 |
| Potassium Chloride | 36 | $1,139 | $32 |
| Levothyroxine | 36 | $1,078 | $30 |
| Furosemide | 133 | $1,050 | $8 |
| Diltiazem 24hr Er (Cd) | 16 | $787 | $49 |
| Spironolactone | 85 | $751 | $9 |
| Pantoprazole | 25 | $654 | $26 |
| Simvastatin | 62 | $564 | $9 |
| Warfarin | 35 | $542 | $15 |
| Finasteride | 13 | $363 | $28 |
| Lisinopril-Hydrochlorothiazide | 11 | $321 | $29 |
| Atenolol | 21 | $318 | $15 |
| Verapamil Er | 14 | $309 | $22 |
| Clonidine | 15 | $290 | $19 |
| Torsemide | 12 | $265 | $22 |
| Benazepril | 14 | $201 | $14 |
| Ramipril | 27 | $180 | $7 |
2020: 43 drugs
| Eliquis | 239 | $258,975 | $1,084 |
| Xarelto | 107 | $120,964 | $1,131 |
| Vascepa | 150 | $106,563 | $710 |
| Brilinta | 73 | $56,488 | $774 |
| Ranolazine Er | 135 | $35,711 | $265 |
| Entresto | 31 | $33,663 | $1,086 |
| Livalo | 14 | $11,050 | $789 |
| Metoprolol | 437 | $10,172 | $23 |
| Repatha Sureclick | 12 | $8,245 | $687 |
| Atorvastatin | 297 | $5,677 | $19 |
| Bystolic | 14 | $4,824 | $345 |
| Rosuvastatin | 86 | $4,679 | $54 |
| Amiodarone | 45 | $4,288 | $95 |
| Isosorbide Mononitrate Er | 149 | $3,685 | $25 |
| Losartan | 246 | $3,637 | $15 |
| Losartan-Hydrochlorothiazide | 36 | $3,340 | $93 |
| Pravastatin | 152 | $2,696 | $18 |
| Sotalol | 69 | $1,963 | $28 |
| Lisinopril | 180 | $1,753 | $10 |
| Isosorbide Dinitrate | 15 | $1,591 | $106 |
| Ezetimibe | 28 | $1,536 | $55 |
| Hydralazine | 73 | $1,535 | $21 |
| Flecainide Acetate | 12 | $1,380 | $115 |
| Amlodipine Besylate | 142 | $1,360 | $10 |
| Prasugrel | 14 | $1,356 | $97 |
| Nitroglycerin | 60 | $1,284 | $21 |
| Hydrochlorothiazide | 138 | $1,222 | $9 |
| Metoprolol | 127 | $1,130 | $9 |
| Propafenone | 16 | $1,054 | $66 |
| Carvedilol | 83 | $1,030 | $12 |
| Digoxin | 16 | $867 | $54 |
| Clopidogrel | 43 | $807 | $19 |
| Diltiazem 24hr Er | 11 | $708 | $64 |
| Bisoprolol | 16 | $669 | $42 |
| Furosemide | 81 | $664 | $8 |
| Potassium Chloride | 25 | $580 | $23 |
| Simvastatin | 45 | $393 | $9 |
| Warfarin | 24 | $381 | $16 |
| Spironolactone | 40 | $296 | $7 |
| Clonidine | 20 | $285 | $14 |
| Atenolol | 15 | $187 | $12 |
| Benazepril | 11 | $162 | $15 |
| Ramipril | 11 | $157 | $14 |
2019: 38 drugs
| Eliquis | 197 | $161,509 | $820 |
| Vascepa | 96 | $67,976 | $708 |
| Xarelto | 65 | $57,836 | $890 |
| Brilinta | 94 | $50,781 | $540 |
| Ranolazine Er | 94 | $37,368 | $398 |
| Ranexa | 34 | $18,904 | $556 |
| Entresto | 14 | $10,042 | $717 |
| Metoprolol | 378 | $8,129 | $22 |
| Livalo | 12 | $5,705 | $475 |
| Bystolic | 14 | $5,017 | $358 |
| Atorvastatin | 238 | $4,388 | $18 |
| Amiodarone | 59 | $3,745 | $63 |
| Rosuvastatin | 62 | $3,706 | $60 |
| Prasugrel | 11 | $3,148 | $286 |
| Isosorbide Mononitrate Er | 128 | $3,145 | $25 |
| Diltiazem 24hr Er (Cd) | 13 | $2,777 | $214 |
| Pravastatin | 154 | $2,692 | $17 |
| Isosorbide Dinitrate | 18 | $1,997 | $111 |
| Losartan | 187 | $1,929 | $10 |
| Sotalol | 39 | $1,854 | $48 |
| Ezetimibe | 29 | $1,586 | $55 |
| Lisinopril | 161 | $1,375 | $9 |
| Amlodipine Besylate | 138 | $1,361 | $10 |
| Hydralazine | 74 | $1,241 | $17 |
| Carvedilol | 77 | $1,235 | $16 |
| Metoprolol | 131 | $1,084 | $8 |
| Nitroglycerin | 52 | $842 | $16 |
| Hydrochlorothiazide | 82 | $723 | $9 |
| Clopidogrel | 22 | $688 | $31 |
| Furosemide | 85 | $606 | $7 |
| Losartan-Hydrochlorothiazide | 48 | $587 | $12 |
| Esomeprazole Magnesium | 13 | $458 | $35 |
| Simvastatin | 49 | $448 | $9 |
| Potassium Chloride | 15 | $433 | $29 |
| Flecainide Acetate | 11 | $372 | $34 |
| Atenolol | 24 | $290 | $12 |
| Spironolactone | 37 | $268 | $7 |
| Lisinopril-Hydrochlorothiazide | 13 | $200 | $15 |
2018: 30 drugs
| Eliquis | 166 | $103,581 | $624 |
| Ranexa | 80 | $43,534 | $544 |
| Brilinta | 45 | $19,775 | $439 |
| Prasugrel | 41 | $9,274 | $226 |
| Livalo | 14 | $5,309 | $379 |
| Metoprolol | 256 | $4,424 | $17 |
| Amiodarone | 69 | $3,375 | $49 |
| Atorvastatin | 119 | $2,080 | $17 |
| Isosorbide Mononitrate Er | 96 | $1,459 | $15 |
| Valsartan | 25 | $1,427 | $57 |
| Pravastatin | 128 | $1,401 | $11 |
| Rosuvastatin | 38 | $1,297 | $34 |
| Ezetimibe | 19 | $1,206 | $63 |
| Losartan | 102 | $937 | $9 |
| Lisinopril | 131 | $844 | $6 |
| Carvedilol | 67 | $741 | $11 |
| Metoprolol | 103 | $627 | $6 |
| Hydralazine | 49 | $618 | $13 |
| Sotalol | 14 | $561 | $40 |
| Nitroglycerin | 23 | $509 | $22 |
| Amlodipine Besylate | 77 | $400 | $5 |
| Hydrochlorothiazide | 50 | $342 | $7 |
| Potassium Chloride | 15 | $341 | $23 |
| Losartan-Hydrochlorothiazide | 27 | $298 | $11 |
| Furosemide | 55 | $240 | $4 |
| Clopidogrel | 11 | $235 | $21 |
| Spironolactone | 31 | $198 | $6 |
| Simvastatin | 37 | $191 | $5 |
| Warfarin | 11 | $92 | $8 |
| Atenolol | 13 | $85 | $7 |
2017: 25 drugs
| Eliquis | 113 | $58,033 | $514 |
| Ranexa | 57 | $36,829 | $646 |
| Effient | 28 | $15,658 | $559 |
| Brilinta | 44 | $14,810 | $337 |
| Prasugrel | 15 | $6,498 | $433 |
| Amiodarone | 56 | $4,264 | $76 |
| Metoprolol | 199 | $3,405 | $17 |
| Valsartan | 34 | $1,456 | $43 |
| Atorvastatin | 99 | $1,311 | $13 |
| Isosorbide Mononitrate Er | 79 | $998 | $13 |
| Hydralazine | 60 | $821 | $14 |
| Rosuvastatin | 21 | $680 | $32 |
| Pravastatin | 67 | $640 | $10 |
| Carvedilol | 75 | $602 | $8 |
| Sotalol | 20 | $560 | $28 |
| Nitroglycerin | 22 | $486 | $22 |
| Losartan | 68 | $406 | $6 |
| Metoprolol | 62 | $380 | $6 |
| Lisinopril | 92 | $367 | $4 |
| Losartan-Hydrochlorothiazide | 17 | $255 | $15 |
| Simvastatin | 37 | $214 | $6 |
| Amlodipine Besylate | 41 | $161 | $4 |
| Furosemide | 30 | $141 | $5 |
| Spironolactone | 24 | $140 | $6 |
| Hydrochlorothiazide | 29 | $117 | $4 |
2016: 25 drugs
| Eliquis | 64 | $32,373 | $506 |
| Ranexa | 52 | $23,480 | $452 |
| Effient | 40 | $20,875 | $522 |
| Brilinta | 26 | $8,122 | $312 |
| Crestor | 16 | $4,879 | $305 |
| Metoprolol | 146 | $2,869 | $20 |
| Valsartan | 29 | $1,318 | $45 |
| Amiodarone | 20 | $1,246 | $62 |
| Atorvastatin | 67 | $1,149 | $17 |
| Isosorbide Mononitrate Er | 79 | $850 | $11 |
| Pravastatin | 45 | $565 | $13 |
| Hydralazine | 31 | $539 | $17 |
| Carvedilol | 64 | $496 | $8 |
| Losartan | 51 | $398 | $8 |
| Metoprolol | 48 | $298 | $6 |
| Rosuvastatin | 11 | $293 | $27 |
| Simvastatin | 43 | $282 | $7 |
| Nitrostat | 12 | $279 | $23 |
| Amlodipine Besylate | 46 | $227 | $5 |
| Lisinopril | 55 | $165 | $3 |
| Clopidogrel | 16 | $134 | $8 |
| Sotalol | 17 | $130 | $8 |
| Benazepril | 11 | $79 | $7 |
| Furosemide | 20 | $63 | $3 |
| Hydrochlorothiazide | 15 | $35 | $2 |
2015: 24 drugs
| Ranexa | 46 | $19,762 | $430 |
| Eliquis | 41 | $16,498 | $402 |
| Effient | 35 | $13,829 | $395 |
| Crestor | 29 | $9,722 | $335 |
| Brilinta | 30 | $8,451 | $282 |
| Metoprolol | 116 | $2,087 | $18 |
| Isosorbide Mononitrate Er | 94 | $1,264 | $13 |
| Valsartan | 25 | $1,156 | $46 |
| Atorvastatin | 51 | $1,014 | $20 |
| Hydralazine | 43 | $541 | $13 |
| Pravastatin | 31 | $435 | $14 |
| Carvedilol | 61 | $386 | $6 |
| Amlodipine Besylate | 51 | $296 | $6 |
| Lisinopril | 68 | $269 | $4 |
| Simvastatin | 52 | $236 | $5 |
| Losartan | 26 | $221 | $9 |
| Nitrostat | 12 | $200 | $17 |
| Metoprolol | 34 | $198 | $6 |
| Warfarin | 21 | $178 | $8 |
| Spironolactone | 18 | $147 | $8 |
| Clopidogrel | 11 | $117 | $11 |
| Furosemide | 19 | $108 | $6 |
| Amiodarone | 13 | $91 | $7 |
| Hydrochlorothiazide | 20 | $62 | $3 |
2014: 27 drugs
| Ranexa | 94 | $31,583 | $336 |
| Effient | 89 | $28,511 | $320 |
| Crestor | 54 | $11,988 | $222 |
| Brilinta | 35 | $8,874 | $254 |
| Xarelto | 20 | $6,640 | $332 |
| Diovan | 20 | $5,068 | $253 |
| Isosorbide Mononitrate Er | 259 | $3,541 | $14 |
| Metoprolol | 122 | $2,592 | $21 |
| Atorvastatin | 69 | $1,372 | $20 |
| Hydralazine | 46 | $954 | $21 |
| Bystolic | 11 | $950 | $86 |
| Pravastatin | 30 | $690 | $23 |
| Clopidogrel | 57 | $645 | $11 |
| Metoprolol | 98 | $604 | $6 |
| Cilostazol | 26 | $576 | $22 |
| Lisinopril | 69 | $437 | $6 |
| Carvedilol | 47 | $426 | $9 |
| Amlodipine Besylate | 49 | $405 | $8 |
| Amiodarone | 12 | $399 | $33 |
| Simvastatin | 51 | $347 | $7 |
| Losartan | 11 | $231 | $21 |
| Spironolactone | 17 | $153 | $9 |
| Ramipril | 12 | $149 | $12 |
| Furosemide | 29 | $147 | $5 |
| Atenolol | 11 | $103 | $9 |
| Warfarin | 12 | $70 | $6 |
| Hydrochlorothiazide | 13 | $62 | $5 |
2013: 21 drugs
| Ranexa | 64 | $21,734 | $340 |
| Effient | 43 | $15,103 | $351 |
| Crestor | 33 | $5,996 | $182 |
| Brilinta | 20 | $4,873 | $244 |
| Xarelto | 18 | $4,824 | $268 |
| Diovan | 34 | $4,610 | $136 |
| Livalo | 12 | $2,754 | $230 |
| Isosorbide Mononitrate Er | 176 | $2,444 | $14 |
| Clopidogrel | 76 | $2,265 | $30 |
| Metoprolol | 82 | $2,136 | $26 |
| Hydralazine | 53 | $1,039 | $20 |
| Atorvastatin | 42 | $996 | $24 |
| Bystolic | 13 | $977 | $75 |
| Carvedilol | 36 | $540 | $15 |
| Amlodipine Besylate | 81 | $500 | $6 |
| Lisinopril | 71 | $477 | $7 |
| Metoprolol | 75 | $362 | $5 |
| Clonidine | 17 | $260 | $15 |
| Simvastatin | 21 | $159 | $8 |
| Ramipril | 12 | $151 | $13 |
| Furosemide | 28 | $141 | $5 |
Money from drug and device companies
$200 in 2025
| 2025 | 3 | 3 | None | $200 |
| 2024 | 5 | 7 | None | $456 |
| 2023 | 1 | 1 | None | $84 |
| 2022 | 2 | 4 | None | $85 |
| 2021 | 1 | 2 | None | $54 |
| 2020 | 1 | 3 | None | $79 |
| 2019 | 3 | 6 | None | $119 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biotronik | Acticor 7 Vr-T Dx | $167 | 1 payment
|
| Baxter Healthcare | Hillrom - Carnation Ambulatory Monitor | $19 | 1 payment
|
| Philips North America | Extended Holter | $14 | 1 payment
|
See all 3 published payments
| Biotronik | Meals · 2025-09-18 | Acticor 7 Vr-T Dx | $167 |
| Philips North America | Meals · 2025-05-06 | Extended Holter | $14 |
| Baxter Healthcare | Meals · 2025-01-07 | Hillrom - Carnation Ambulatory Monitor | $19 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $456
| ShockWave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $199 | 1 payment
|
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $153 | 1 payment
|
| Baxter Healthcare | Hillrom - Carnation Ambulatory Monitor | $46 | 2 payments
|
| Philips North America | (5044) Mcot | $36 | 2 payments
|
| Abbott Laboratories | Diamondback Coronary | $23 | 1 payment
|
2023: $84
| Inari Medical | Flowtriever Catheter, S | $84 | 1 payment
|
2022: $85
| Amgen | Repatha | $73 | 3 payments
|
| Novartis Pharmaceuticals | Entresto | $12 | 1 payment
|
2021: $54
| Amgen | Repatha | $54 | 2 payments
|
2020: $79
| Amgen | Repatha | $79 | 3 payments
|
2019: $119
| Amgen | Repatha | $85 | 4 payments
|
| Novartis Pharmaceuticals | Entresto | $23 | 1 payment
|
| Medtronic Vascular | Reveal Linq | $11 | 1 payment
|
Checkups this office reported
8 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Advance care plan on fileOlder patients with an advance care plan or a documented conversation about one | 100%That's most of the people this applied to. | 709 |
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 100%That's most of the people this applied to. | 139 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 98%That's most of the people this applied to. | 555 |
| Medications listed in the chartVisits where the current medication list was documented | 99%That's most of the people this applied to. | 1,806 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 97%That's most of the people this applied to. | 346 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 98%That's most of the people this applied to. | 857 |
| Risky medications in older adultsOlder patients given a medication that is risky at their age | 0%That's few of the people this applied to. Better on this measure. | 714 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 100%That's most of the people this applied to. | 907 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Did a security review of patient data
- Exchanges records both ways with other health systems
- Implementation of improvements that contribute to more timely communication of test results
- Implementation of medication management practice improvements
- Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
- Reports cases to public health electronically
- Screens for social needs
- Exempt from immunization registry reporting
- Exempt from query of the prescription drug monitoring program (pdmp)
Professional record
- NPI
- 1639375959
- Licence
- AZ 36465
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 5339 Prospect Rd # 286, San Jose, CA, 95129
- NPI first listed
- 2007-06-24
- NPI last updated
- 2011-11-22
This is when the NPI record was last certified, not a medical board exam.